Document Detail

The effects of benzodiazepine use during pregnancy and lactation.
MedLine Citation:
PMID:  7881198     Owner:  NLM     Status:  MEDLINE    
Although there are a number of studies and individual case reports concerning the use of benzodiazepines in human pregnancy, the data concerning teratogenicity and effects on postnatal development and behaviour are inconsistent. There is evidence from studies in the 1970s that first trimester exposure to benzodiazepines in utero has resulted in the birth of some infants with facial clefts, cardiac malformations, and other multiple malformations, but no syndrome of defects. Diazepam and chlordiazepoxide are amongst the drugs most frequently implicated in the earlier studies. However, data from later studies provide no clear evidence of significant increase in either the overall incidence of malformations or of any particular type of defect. Many of the women included in these studies has psychiatric illnesses, epilepsy, or diabetes all of which have an intrinsic risk in pregnancy, and some were on multidrug therapy. Medical-obstetric histories and family history of malformations were not always presented in the publications, which makes assessment of risk associated with benzodiazepine use per se difficult. Nevertheless, in most of the studies involving first trimester use of benzodiazepines, the majority of infants were normal at birth and had normal postnatal development. Late third trimester use and exposure during labour seems to be associated with much greater risks to the fetus/neonate. Some, but by no means all infants exposed at this time, exhibit either the floppy infant syndrome, or marked neonatal withdrawal symptoms. Symptoms vary from mild sedation, hypotonia, and reluctance to suck, to apnoeic spells, cyanosis, and impaired metabolic responses to cold stress. These symptoms have been reported to persist for periods from hours to months after birth. This correlates well with the pharmacokinetic and placental transfer of the benzodiazepines and their disposition in the neonate. However, there has been no significant increase in the incidence of neonatal jaundice and kernicterus in term infants. The prolonged use of benzodiazepines throughout pregnancy raised the concern that there may be altered transmitter synthesis and function, leading to neurobehavioural problems in the children. In approximately 550 children who were followed up for various times up to four years of age, there is no increase in either the malformation rate or adverse effects on neurobehavioural development and IQ. Although some of the data indicate that a small number of children were slower to develop during the first year or so, they did exhibit catch up growth and most had developed normally by four years of age. Where developmental deficits persisted, it was not possible to prove a cause-effect relationship with benzodiazepine exposure. These children were often from families where there was maternal illness requiring prolonged drug therapy or where there were social problems. It is important to consider poor environmental and social factors when assessing the possible prenatal influence of the benzodiazepines on the postnatal health and development of the child. There is evidence that clonazepam, clorazepate, diazepam, lorazepam, midazolam, nitrazepam, and oxazepam are excreted into breast milk. The published data indicate that the levels detected in breast milk are low; therefore, the suckling infant is unlikely to ingest significant amounts of the drug in this way. Problems may arise if the infant is premature or has been exposed to high concentrations of drug either during pregnancy or at delivery.
P R McElhatton
Related Documents :
2125228 - A cost-benefit/cost-effectiveness analysis of smoking cessation for pregnant women.
18717188 - Regression analysis of maternal smoking effect on birth weight.
617308 - The narcotic-dependent mother: fetal and neonatal consequences.
10956448 - Perinatal complications associated with maternal tobacco use.
2244608 - Midfacial hypoplasia associated with long-term intubation for bronchopulmonary dysplasia.
2754068 - Transient blueberry muffin appearance of a newborn with congenital monoblastic leukemia.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Reproductive toxicology (Elmsford, N.Y.)     Volume:  8     ISSN:  0890-6238     ISO Abbreviation:  Reprod. Toxicol.     Publication Date:    1994 Nov-Dec
Date Detail:
Created Date:  1995-04-12     Completed Date:  1995-04-12     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  8803591     Medline TA:  Reprod Toxicol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  461-75     Citation Subset:  IM    
Teratology Information Service, UMDS, St. Thomas' Hospital, London, England.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Abnormalities, Drug-Induced / etiology*
Anti-Anxiety Agents / adverse effects*,  pharmacokinetics
Infant, Newborn
Maternal-Fetal Exchange / physiology
Milk, Human / metabolism*
Pregnancy / physiology*
Prenatal Exposure Delayed Effects*
Reg. No./Substance:
0/Anti-Anxiety Agents; 12794-10-4/Benzodiazepines

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The global bifurcation structure of the BVP neuronal model driven by periodic pulse trains.
Next Document:  Mechanisms of the stimulation of rat uterine peroxidase activity by methoxychlor.